The authorization is discretionary with no obligation to repurchase. Monitor future 10-Q and 10-K filings for actual repurchase activity and any changes to the company's cash position or debt levels.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $68.12entry
- T+1 · 13d ago +1.25%α −0.40% · $68.97
- T+5 · 7d ago −5.84%α −5.26% · $64.14
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
PTC Therapeutics announced a $500 million share repurchase program authorized by its Board of Directors. The program allows management to repurchase shares through open-market transactions, privately negotiated deals, or accelerated repurchases at its discretion. No financial results or guidance were provided in this filing.
Key Facts
- Board authorized a share repurchase program of up to $500 million of common stock
- Repurchases may be made at management's discretion through open-market transactions, privately negotiated transactions, accelerated share repurchases, and other methods
- The program is subject to market conditions
- No timeline or commitment to execute any repurchases was stated
- Market cap is $5.4 billion, making the authorization approximately 9.3% of market cap
Financial Impact
Up to $500 million share repurchase authorization, representing about 9.3% of current market cap
Risk Factors
- Authorization does not obligate the company to repurchase any shares
- Repurchases could reduce cash reserves available for operations or business development
- No financial results or guidance were provided to assess the company's ability to fund the program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-121713 |
| Document: tmb-ex99d1.htm | 0001104659-26-121713 |
| Document: 0001104659-26-121713-index-headers.html | 0001104659-26-121713 |
| Document: 0001104659-26-121713-index.html | 0001104659-26-121713 |
| Document: 0001104659-26-121713.txt | 0001104659-26-121713 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Viewing Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers